explore -WSS

explore

author：explore 2025-10-01 23:38:36 - browse：8177

Grail spent more than $1 million last quarter lobbying Congress, underscoring the urgency of the company’s bid to secure Medicare coverage for its pricey blood-based cancer screening test that has been on the market for over a year but is not widely used.

A recently posted lobbying report indicates that, during the fourth quarter of last year, the biotech spent $1.07 million on “issues related to oncology and multi-cancer early detection,” including House and Senate bills that would allow Medicare to cover multi-cancer screening tests. That figure has been rising; during the fourth quarter of 2021, the company spent $470,000 on lobbying. That’s far more than cancer and genetic testing biotechs such as Guardant Health, Myriad Genetics, and Tempus, which spent anywhere from $90,000 to nearly $300,000 on lobbying last quarter.

The growing investment in lobbying elected officials comes at a time when Grail is looking to make its test, Galleri, available to a broader swath of the population. The test, launched in 2021, can detect early signs of more than 50 cancers among people who don’t have symptoms. That’s because cancer cells release bits of DNA into the bloodstream, and Galleri spots telltale modifications to this DNA.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Trump demands the U.S. pay no more for drugs than other countries … again
Next article： 'Cuddling' is just what the doctor ordered for a 200

WSS

Medical mystery: When an infection after surgery isn’t what it seems

A new ‘biological computer' targets cancer while sparing healthy cells

Jan. 6 charges against Trump would add to his mounting legal peril as he campaigns for 2024

Jesse Tyler Ferguson makes friendship bracelets for Taylor Swift's Eras Tour

What to know about 'Guardians of the Galaxy Vol. 3' as it hits Disney+

Parkland mass shooting to be reenacted for lawsuit

leisure time

explore

hotspot

State Dept. review finds Biden bears some blame for Afghanistan failures

US Marines prepare to be put on commercial ships to deter Iranian harassment in Strait of Hormuz

BioMarin wins approval for gene therapy to treat hemophilia A

There’s a way to spot data fakery. All journals should be using it

Novavax promises a turnaround & Lilly roils the obesity market

In rare move, senator releases unverified FBI source report alleging Biden bribe

Hepatitis C has a cure — but many Americans still lack access to it

US Marines prepare to be put on commercial ships to deter Iranian harassment in Strait of Hormuz

Dobbs anniversary: the lost opportunity of abortion as health care

'Golden Bachelor' Gerry Turner reveals what he wants in a partner and more

focus

Extensive review finds private equity owners jack up cost of care

Eli Lilly to acquire DICE Therapeutics in $2.4 billion deal

The stock market has soared this year, but will it last? Experts weigh in

Rivals hope for voter 'fatigue' as Trump's woes mount but base stays loyal: ANALYSIS

Lifetime voting ban for felony convictions struck down in Mississippi

Are infertility treatments 'essential' during the Covid

leisure time

focus

explore

leisure time